Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) [Phase 3]

View source ↗

Summary

Roche's Phase 3 study of gantenerumab in individuals at risk for or in the earliest stages of Alzheimer's disease was terminated, with results posted July 9, 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Gantenerumab (gantenerumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Alzheimers Disease | Phase 3 | Status: TERMINATED | Results posted: 2024-07-09